{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"1"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"7"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Progression of Disease (POD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)","groups":[{"description":"Gemcitabine, Docetaxel, Bevacizumab","id":"OG000","title":"Gemcitabine, Docetaxel, Bevacizumab"},{"description":"Gemcitabine, Docetaxel, Placebo","id":"OG001","title":"Gemcitabine, Docetaxel, Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months","title":"Overall Objective Response","type":"PRIMARY","unitOfMeasure":"participants"}